Skip to content

The effect of Coughstop Barij Syrup on children's cough

The effect of Coughstop Barij Syrup on children's cough and its comparison with Dextromethorphan

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200908048662N1
Enrollment
80
Registered
2021-11-02
Start date
2020-01-21
Completion date
Unknown
Last updated
2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cough.

Interventions

Intervention 1: Intervention group: Coughstop Barij® Syrup was made by Barij Essence Pharmaceutical Company. Syrup 60 ml, containing Thymus vulgaris and Hedera helix. Dosage of the drug in the age gro

Sponsors

Kashan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 12 Years

Inclusion criteria

Inclusion criteria: Coughing Cough duration less than 3 weeks Age 2 to 12 years

Exclusion criteria

Exclusion criteria: Having allergies or contraindications to dextromethorphan or coughstop syrup Existence of chronic conditions that require long-term pharmacological treatment. Fever Taking antibiotics Participate in other trials during the last 15 days

Design outcomes

Primary

MeasureTime frame
Check the quality of the cough. In each study, the level of recovery was complete recovery (complete cessation of cough), Relative recovery (patient is satisfied with the reduction of cough or the duration of cough is halved), No improvement (the drug does not change the severity of the cough) is assessed. Timepoint: At the beginning of the study (before the intervention) And 24, 48 and 96 hours after the start of treatment. Method of measurement: Visual Analog Scale.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactmohammad reza sharif

Kashan University of Medical Sciences

mrsharifmd@yahoo.com+98 31 5544 3022

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026